Advanced Search

 

Study ID Status Title Patient Level Data
104864/204 Completed A Phase II study to determine the efficacy and safety of 2.3 mg/m2 oral topotecan daily for 5 days every 21 days in patients with advanced non-small cell lung cancer
104864/213 Completed An Open-label Evaluation of Topotecan Administered Intravenously as Five Daily 30 Minute Infusions every 21 days to Patients with Ovarian Tumors Refractory to Other Therapies.
104864/230 Completed A study to determine the balance/excretion and pharmacokinetics of SKF-104864 given as oral (2.3 mg/m2) or intravenous (iv) (1.5 mg/m2) doses once daily for 5 days to patients with malignant solid tumours
104864/234 Completed Phase II Trial of Topotecan Combined With Cisplatin in Persistent or Recurrent Squamous and Non-squamous Cervical Cancer
104864/250 Completed Phase I/II study of oral topotecan and intravenous paclitaxel in patients with advanced non-small cell lung cancer (phases I and II) and other advanced solid tumors (phase I only)
104864/251 Completed A phase II study to determine the efficacy and safety of topotecan administered intravenously daily for 5 days with a single intravenous dose of carboplatin on Day 1 repeated every 21 days in patients with advanced non-small cell lung cancer
104864/271 Completed Phase I/II trial of oral topotecan and oral etoposide in untreated extensive disease small cell lung carcinoma
104864/272 Completed Etoposide, Topotecan and Paclitaxel, “Etopotax” in Patients with Refractory Malignancy: A Phase I Trial
104864/386 Completed An open-label, multicenter, randomized, phase II study of 5-day oral topotecan vs. 21-day oral topotecan vs. CPT-11 (Irinotecan) for second-line therapy in patients with colorectal carcinoma
104864/396 Completed An open-label, multicentre, randomised, phase III comparator study of oral topotecan versus intravenous topotecan for second-line therapy in patients with SCLC who have relapsed greater than or equal to 90 days after completion of first-line therapy
104864/405 Completed An Open Label, Multicenter, Randomized, Phase II Study of Topotecan and Paclitaxel vs. Etoposide/Cisplatin as First Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer
104864/410 Completed A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer
104864/435 Completed A Phase II Study of Topotecan and Paclitaxel as First-Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer
104864/438 Completed Phase I Study of Oral Topotecan in Patients with Hematological Myeloid Malignancies
104864/478 Completed An Open-Label, Multicentre, Randomised, Phase III Comparator Study of Active Symptom Control alone or in Combination with Oral Topotecan in Patients with Relapsed Resistant SCLC
104864/502 Completed An Open-Label, Multicenter, Randomized, Phase II Study of Oral Topotecan Daily x 5 Days vs. Oral Topotecan 5 Days On, 2 Days Off for 3 Weeks for Second-Line Treatment in Patients with Recurrent, Locally Advanced or Metastatic Cervical Cancer
104864/507 Completed Phase I Study of the Effect of Oral Cyclosporin A on the Pharmacokinetics of Oral Topotecan
104864/511 Completed A Phase I open label study to assess the safety, tolerability, and efficacy of oral etoposide and oral topotecan administered in combination to patients with small-cell lung cancer who have not previously received chemotherapy
104864/517 Terminated A Phase I study of oral topotecan as a radiosensitizing agent in patients with rectal cancer
104864/535 Completed A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer with Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
104864/552 Completed A Phase II, Multicentre, Open Label Study of Oral Topotecan and Cisplatin in Ovarian Cancer Recurring ≥6 Months Following Initial Platinum-based Chemotherapy
104864/557 Completed A Phase II Trial Of Topotecan and Cisplatin In Patients With Metastatic Or Recurrent Squamous Cell Carcinoma Of The Cervix
104864/612 Completed A prospective, open label phase II study to evaluate the efficacy and safety of topotecan (Hycamtin) in combination with carboplatin as first-line chemotherapy in patients with ovarian cancer.
104864/615 Completed WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMPARED TO DOCETAXEL IN PATIENTS WITH PRETREATED ADVANCED NSCLC: AN OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL
104864/623 Completed An Open Label, Multicenter, Non-Comparative Phase II Study of Weekly Intravenous Vinorelbine and Topotecan in Chemotherapy-Nave Patients with Advanced Non-Small Cell Lung Cancer

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.